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Glomerular injuryHypertension is a prevalent disorder in the world representing one of the major risk factors for heart attack and
stroke. These risks are increased in salt sensitive individuals. Hypertension and salt sensitivity are complex
phenotypeswhose pathophysiology remains poorly understood and, remarkably, salt sensitivity is still laborious
to diagnose.
Here we present a urinary proteomic study speciﬁcally designed to identify urinary proteins relevant for the
pathogenesis of hypertension and salt sensitivity. Despite previous studies that underlined the association of
UMOD gene variants with hypertension, this work provides novel evidence showing different uromodulin
protein level in the urine of hypertensive patients compared to healthy individuals. Notably, we also show that
patients with higher level of uromodulin are homozygous for UMOD risk variant and display a decreased level
of salt excretion, highlighting the essential role of UMOD in the regulation of salt reabsorption in hypertension.
Additionally, we found that urinary nephrin 1, amarker of glomerular slit diaphragm,may predict a salt sensitive
phenotype and positively correlate with increased albuminuria associated with this type of hypertension.
© 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Hypertension is a very common disease, especially in industrialized
countries where it is becoming an important issue of public health.
Many cases of hypertension are related to incorrect behaviors as a
high-fat diet, smoking, and sedentary lifestyle. Hypertension is a very
complex disease and even several genetic association studies have
been published up to now, these variants explain approximately 20%
[1] of the population variation in blood pressure (BP). Clinical and
experimental studies have highlighted the implications of abnormal
sodium balance in the development of hypertension in both animald chromatography coupled to
alt sensitive; SR, salt resistant;
eOntology;MBP,mean BP.
lecular Oncology, Via Adamello
9 02574303244.
. This is an open access article undermodels and humans [2–5]. Generally, the response of BP changes in
sodium assumptions is heterogeneous, approximately half of the
population with essential hypertension is salt-sensitive as increases BP
in response to a salt intake [6]. Salt-sensitive individuals are more
prone to develop hypertension which is characterized by glomerular
hypertension,microalbuminuria [7] and a highermortality andmorbid-
ity of cardiovascular events [7,8]. For these individuals, there is no uni-
versal consensus of deﬁnition or a proper test to assess salt sensitivity.
Commonly used tests measure BP response to a change in dietary salt
intake. These tests are laborious, expensive andwith low patient's com-
pliance [9]. Indeed, the discovery of novel markers of salt sensitivity
would be extremely beneﬁcial in focusing treatment with dietary salt
restriction only to those patients who really beneﬁt from this therapy.
Furthermore, understanding the pathophysiology of hypertension itself
might further drive to more speciﬁc therapeutic targets for lowering BP
and preserving renal function.
Recent advances in clinical research provided by proteomic strate-
gies have accelerated the discovery of urinary biomarkers for kidney
diseases [10–14] as well as coronary artery disease [14,15] and diabeticthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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urinary proteome of hypertensive patients [18] in order to discover
novel pathways involved in the pathogenesis of hypertension and to
identify predictive biomarkers for salt-sensitivity.
2. Experimental procedures
2.1. Patients' selection and study protocol for salt-sensitivity characterization
We enrolled newly discovered, never treated, mild hypertensive
male patients in the ‘Outpatient Clinic for Hypertension’ of San Raffaele
Hospital, Milan. The Ethics Committee of the Hospital approved the
study and a written informed consent was obtained from each individ-
ual. The study protocol for the acute salt load test was similar to that re-
ported previously [19]. Brieﬂy, the protocol began with a 2-hour
equilibration period during which the subjects were taken to a quiet
room and a venous catheter was inserted into an antecubital vein.
They remained in the supine position until the end of the salt loading
except for voiding. A steady state was considered to be achieved when
the volumeof urine collection and the values of the BP recordings varied
by b1 mL/min and b3 mm Hg, respectively. The average equilibration
period lasted 2 h.
Acute salt load test: after the equilibration period and achievement
of a steady state, a constant-rate i.v. infusion of 2 L of 0.9% NaCl was
carried out in 2 h. BP (mean of 3 measurements taken 3 min apart)
was measured every 30 min during the 2 h of loading and 3 times at
3-minute intervals at the end of the infusion. These last 3 BP values
were averaged and used in the analysis.
Patientswere deﬁned salt resistant (SR) or salt sensitive (SS) accord-
ing to mean BP changes after acute saline infusion: those that displayed
a mean BP increase greater than 4 mm Hg were considered salt sensi-
tive. Conversely, patients with a smaller or negative BP change resulted
salt resistant. Urines for proteomic analysis were collected during the
equilibration period before the acute salt load.
Inclusion criteria for the study were: sex male, age between 18 and
55 years; body mass index (BMI) of b30 kg/m2; salt intake, evaluated
as urinary Na excretion, b300 mEq/24 h; ambulatory systolic BP (SBP)
of N140 mm Hg and diastolic BP (DBP) of N90 mm Hg in 3 consecutive
visits at their family doctors. Exclusion criteria included history of
myocardial infarction, stroke, congestive heart failure, liver disease,
secondary cause of hypertension, diabetes, severe hypertension
(N160/110 mmHg), abuse of drugs or alcohol, and creatinine clearance
of b80 mL/m. Secondary forms of hypertension (e.g., primary aldoste-
ronism) were ruled out with speciﬁc investigations when deemed
appropriate. Women were excluded from the study as their urinary
proteome might be inﬂuenced by female hormone cycle.
We added in the study a control of healthy donors, all male, normo-
tensive, with regular BMI, andwith no disease assuming that these sub-
jects are salt sensitive or salt resistant subjects according with the
frequency of the general population. Collectively, we analyzed urines
from75 subjects: 19 SS, 37 SR and 19 healthydonors. A cohort of 24 sub-
jects was used for the proteomic analysis, a cohort of 52 subjects for the
validation phase and 56 hypertensive patients for themicroalbuminuria
test. The criterion adopted for the selection of all this subsets is that the
patients are all consecutive. Personnel blind to the salt test results
carried out the proteomic analyses.
2.2. Urine collection and concentration
Urine samples collected from healthy donors and patients were
stored immediately at−80 °C. For each donor, approximately 25 mL
of urinewas centrifuged at 5000×g for 15min at 4 °C to remove cell de-
bris, and were successively concentrated by ultraﬁltration (Microcon
devices YM-10, Millipore, Billerica, MA, USA). Urine was sequentially
passed through a ﬁltration membrane of 10 kDa cut-off at 2500 rpm
and at 4 °C. The ﬁnal concentrate was washed twice with water toremove excess salt occasionally present in urine. Final protein concen-
trationwas estimated by the Bradfordmethod and 50 μg of each sample
was processed by FASP procedure [20].
Urinary albumin and creatinine were measured by immuno-
turbidimetric technique on a Cobas Mira autoanalyzer (Roche, Basel,
Switzerland).
2.3. Protein digestion and peptides preparation
The urinary proteome was digested in-solution with trypsin using
the FASP protocol [20] with spin ultraﬁltration units of nominal
molecular weight cut off of 30,000 Da. Brieﬂy, 200 μL of urinary proteins
containing 50 μg of protein concentrates was reduced by adding 50 μL
of 0.5 M DTT and 1 M Tris/HCl pH 8.5 and incubating the samples for
1 min at 95 °C, samples were centrifuged at 14,000 ×g at 4 °C for
15 min. 200 μL of 8 M urea in 0.1 M Tris/HCl, pH 8.5 (UA) was added
to the supernatant and the samples were transferred to YM-30
Microcon ﬁlters (Cat No. MRCF0R030, Millipore). Samples were centri-
fuged at 14,000 ×g for 15 min. Then, 50 μL of 0.05 M iodoacetamide in
8 M urea was added to the ﬁlters and the samples were incubated in
the dark for 5 min. Filters were washed twice with 100 μL of 8 M UA
followed by two washes with 100 μL of 40 mM NH4HCO3. Finally,
0.8 μg of trypsin was added in 40 μL of 40 mM NH4HCO3 to each ﬁlter.
Samples were incubated overnight at 37 °C and the released peptides
were collected by centrifugation. The resulting peptides were puriﬁed
on a C18 StageTip (Proxeon Biosystems, Denmark) [21]. For the analysis
of technical replicates, the peptides' concentrate was divided into three
independent samples.
2.4. Mass spectrometry analysis and proteins quantitation
Mass spectrometry analysis was performed by LC–MS/MS using an
LTQ-Orbitrap mass spectrometer (ThermoScientiﬁc, Bremen,
Germany). Puriﬁed tryptic digests were injected in a capillary chromato-
graphic system (EasyLC, Proxeon Biosystems); peptide mixtures were
separated on a homemade 20 cm long fused silica capillary (75-μm
inner diameter, Proxeon Biosystems) ﬁlled with Reprosil-Pur C18 3 μm
resin (Dr. Maisch GmbH, Ammerbuch-Entringen, Germany). A gradient
of eluents A (distilled water with 2% (v/v) acetonitrile, 0.5% (v/v) formic
acid) and B (80% acetonitrile in distilled water with 0.1% (v/v) formic
acid) was used to achieve separation from 4% buffer B to 50% buffer B
in 320min (0.2 μL/min ﬂow rate). MS analysis was performed as report-
ed previously [22].Weused exclusion list for predicted albumin peptides
for all the MS runs. Raw MS ﬁles were processed with MaxQuant soft-
ware (v 1.2.2.5) [21] making use of the Andromeda search engine
[23,24]. MS/MS peak lists were searched against the UniProtKB/Swiss-
Prot protein sequence complete proteome database (release
2011_12 2010_10 of 07-October-2010) in which trypsin speciﬁcity
was used with up to two missed cleavages allowed. Searches were
performed selecting alkylation of cysteine by carbamidomethylation
as ﬁxed modiﬁcation, and oxidation of methionine and N-terminal
acetylation as variable modiﬁcations. Mass tolerance was set to
5 ppm and 0.6 Da for parent and fragment ions, respectively. The
false discovery rate for both peptides and proteins were set at 0.01.
Additionally, we required at least two peptides identiﬁcations per
protein, of which at least one peptide had to be unique to the protein
group. Measurement time for the triplicate analysis was slightly
more than 15 h, and total sample consumption was 4 μg (urinary
sample yields 0.02 mg/mL of proteins).
Label-free analysis was performed using MaxQuant software for
protein quantitation. This included “match between run” option (time
window of 5 min) for the quantiﬁcation of the peptides recognized on
the basis of mass and retention time but identiﬁed in other LC–MS/MS
runs. For label-free proteins quantiﬁcation a minimum ratio counts of
2 was considered and the “LFQ intensities” which are the intensity
values normalized across the entire dataset were used. All the
Table 1
Clinical characteristics of all naïve hypertensive patients enrolled in the present studywho
underwent acute salt load.
Phenotype Salt resistant
n = 37
Salt sensitive
n = 19
P value
Age (years) 42 ± 1.6 43.1 ± 2.1 0.67
BMI (kg/m2) 25 ± 0.4 26.8 ± 0.8 0.071
eGFR (mL/m/1.72 m2) 99.8 ± 0.6 99.6 ± 0.9 0.856
24 h urinary Na (mEq/24 h) 140.8 ± 7.6 167 ± 17.3 0.112
SBP baseline (mm Hg) 142.5 ± 2.1 134.5 ± 2.4 0.032
DBP baseline (mm Hg) 89.6 ± 1.6 84.2 ± 2.2 0.05
SBP T120 (mm Hg) 140.3 ± 2.1 146.2 ± 2.3 0.09
DBP T120 (mm Hg) 86 ± 1.7 91.9 ± 1.8 0.036
ΔSBP (T120 − T0) (mm Hg) −1.8 ± 1 11.7 ± 1 b0.001
ΔDBP (T120 − T0) (mm Hg) −3.7 ± 0.6 7.8 ± 1.03 b0.001
ΔMBP (T120 − T0) (mm Hg) −2.9 ± 0.61 8.77 ± 0.92 b0.001
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relative intensities and search parameters were loaded on Peptide
Atlas repository (accession number http://www.peptideatlas.org/
PASS/PASS00383).
2.5. Bioinformatics and statistical analysis
Biological Networks Gene Ontology (BiNGO) program package
(v 2.44) [25] with the Cytoscape plugin (v 2.8.0) were used to ﬁnd statis-
tically over-represented GeneOntology (GO) categories [26]. Kyoto Ency-
clopedia of Genes andGenomes (KEGG) pathway analysiswas performed
with the KEGG pathway mapper tool (http://www.genome.jp/kegg/tool/
map_pathway2.html) using the Uniprot ID of the modulated proteins.
For patients' study, data are expressed as means ± SEMs. Several
hypotheses were tested with ANOVA using a sequence of least squares
models.
MultiExperiment Viewer software (MeV) (v 4.6.2) was used for hi-
erarchical clustering. Hierarchical trees were constructed for proteins
quantiﬁed (y axis) and samples analyzed (x axis). By using MEV,
T-tests and ANOVA test were applied on each of the intensities of the
quantiﬁed proteins.
2.6. Western Blot analysis and antibodies
20 μg of proteinswas diluted in loading buffer (10 g/L SDS, 10% glyc-
erol, 1% 2-mercaptoethanol, bromophenol blue 20 g/L, 5 mM Tris HCl,
pH 6.8), boiled, separated on a 4–12% gradient SDS-PAGE (NUPAGE
from Invitrogen) and transferred onto nitrocellulose membranes (GE
Healthcare/Amersham Bioscience, United Kingdom) by electroblotting.
Proteins and β-actin abundances in the urine of control group and naïve
patients were quantiﬁed by densitometric analysis. WB analysis was
performed on randomly selected samples.
The following antibodies were used: polyclonal anti-nephrin 1
(H300) antibody produced in rabbit (Santa Cruz Biotechnology, USA),
anti-uromodulin polyclonal antibody produced in sheep (Abcam,
Cambridge, MA), monoclonal anti-ephrin-B2 antibody produced in
mouse and polyclonal anti-IST1 antibody produced in rabbit (both
fromSigma-Aldrich, St. Louis,MO), andmonoclonal anti-actin produced
in mouse (Sigma-Aldrich, St. Louis, MO).
2.7. Genotyping
Genomic DNA was extracted from peripheral blood with standard
method [10]. All of the subjects were genotyped for rs4293393 UMOD
polymorphism (Assay ID C_27865986_10) by a 5′ nuclease allelic
discrimination assay, with allele-speciﬁc MGB probes (TaqMan SNP
Genotyping Assay — Applied Biosystems, Foster City, CA, USA) accord-
ing to manufacturer's instructions.
3. Results
3.1. Patients
Clinical characteristics of all naïve hypertensive patients enrolled in
the study who underwent acute salt load are summarized in Table 1.
In particular, SS displayed a large increase in BPs after saline load,
however in SR a fall in systolic, diastolic and mean BP was observed.
All the other parameters considered were similar at baseline, indicating
a good homogeneity of the study population. Notably, we added in the
study a control of healthy donors, all male, normotensive, with regular
BMI, and with no disease.
3.2. Identiﬁcation of urinary proteome in hypertensive patients
We characterized urines of 24 subjects by quantitative proteomics:
10 SR and 7 SS hypertensive subjects, plus a control of 7 healthynormotensive donors. Brieﬂy, urinary proteins were concentrated,
quantiﬁed and trypsin digested. The peptides resulting from trypsin di-
gestion were desalted and analyzed by LC–MS/MS. All of the samples
were analyzed in triplicate in order to make the data reliable for statis-
tical analysis and to increase protein coverage using stringent protein
identiﬁcation criteria. The false discovery rate for all the proteomic
data was set at 0.01. The total number of identiﬁcations increased
from 419 in single run to 577 in triplicate runs of the same donor
(Supplementary Fig. 1A). This number represents the expected com-
plexity of proteome coverage of a single sample analyzed in triplicate
[18,27].
We performed two sets of experiments using different cohorts of pa-
tients in order to validate protein identiﬁcation and quantitation across
independent analyses (Supplementary Fig. 1B). Technical reproducibil-
ity of label free quantiﬁcation was proven to be excellent and label free
quantiﬁcation showed a very high homogeneity between patients
(Supplementary Fig. 1C). Collectively, we identiﬁed 812 protein groups
(Supplementary Table 1). The overlapping proteins identiﬁed both in
the ﬁrst and in the second sets were about 80% (Supplementary Fig. 2A).
Cellular component Gene Ontology (GO) terms associated to these
proteins are related to extracellular space, cell surface, vacuole, vesicles,
plasma membrane, extracellular matrix, collagen and lysosomal pro-
teins (Supplementary Fig. 2B). These ontologies are consistent with
urine composition.
3.3. Identiﬁcation of urinary markers of hypertension
We quantiﬁed urinary proteins using protein intensity levels
normalized on the total amount of all the identiﬁed proteins (Supple-
mentary Fig. 3A). The majority of the proteins resulted up-regulated in
both SS and SR patients vs. controls and vice versa (Supplementary
Fig. 3C), meaning that most of these proteins reﬂect the effect of hyper-
tension in common to all patients. Each of the quantiﬁed proteins was
further subjected to ANOVA-test allowing the identiﬁcation of 263 pro-
teins undergoing signiﬁcant changes (P value b 0.01) among SR or SS
patients and controls (Supplementary Table 2). As reported in Fig. 1A,
hierarchical trees constructed for proteins quantiﬁed (y axis) and
samples analyzed (x axis) clearly showed the grouping of SS and SR pa-
tients with respect to controls. From ANOVA test, we retrieved informa-
tion on which proteins were differently represented among SR, SS
patients and healthy donors, butwe did not discriminate if the variation
of abundance of these proteinswith respect to controls occurred in both
groups of patients or if it was speciﬁc for one of them. To this aim, pro-
teins signiﬁcantly affected were further subjected to T-tests analysis as
SR vs. C, SS vs. C and SR vs. SS. Fifty six proteins were found up- or
down-regulated both in SS and SR patients with respect to the controls,
suggesting that these proteins could be associated to hypertension in
general (Supplementary Table 3). However, ﬁfty-one proteins were
differently regulated in SS patients as compared to both healthy and
SR subjects (Supplementary Table 4),while 61 proteinswere differently
Fig. 1. Statistical analysis of the quantiﬁed proteins. (A) Hierarchical clustering (HCL) of the proteins differentially expressed (ANOVA P value b 0.01) in the urine of SS and SR patients and
healthy controls C. (B) HCL of the differentially expressed proteins (T test P value b 0.05) in the urine of SS patients vs. Controls (right), SR patients vs. Controls (left) and SS patients vs. SR
patients (middle). Hypertensive patients' specimens co-cluster as well as control ones. Technical replicates of the same sample are always coupled. (C) KEGG pathway analysis of the
signiﬁcant proteins resulting from the ANOVA test: pie chart in terms of numbers of proteins mapped per pathway.
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clearly showed the proper clustering of the three groups (Fig. 1B). By
using the KEGG pathway analysis tool, we found that these proteins
were associated to pathways already known to be involved in hyperten-
sion and salt sensitivity, such as those belonging to the PI3K–Akt signal-
ing, MAPK signaling, complement and coagulation factors [28,29] and
renin–angiotensin system [30], plus others involved in the regulation
of endocytosis [31], actin cytoskeleton and focal adhesion that might
be novel pathways potentially implicated in this pathology (Fig. 1C,
Supplementary Fig. 4).
3.4. Biomarkers veriﬁcation
Proteomic data provide a snapshot of the entire processes behind
the disease under study. In order to unravel the cause/effect events de-
ﬁning this picture we focused on the candidates known to be involved
in the classical BP–kidney relationship. In particular, we validated
nephrin 1 as it resides speciﬁcally in the glomerulus and its presence
in the urine is an indication of podocyte damage [32]. Second, we vali-
dated uromodulin as genome-wide association studies (GWAS) have
identiﬁed susceptibility variants for hypertension in the UMOD gene
[33], and therefore it would be interesting to evaluate its behavior at
the protein level. Third, we validated IST1 as this protein belongs to
the endocytosis pathway and it is involved in the trafﬁc of urinaryexosomes and regulates the ESCORTIII complex [31]. An alteration of
this proteinmightmodify the trafﬁcking of thenumerous ionic channels
along the apical membrane, thus inﬂuencing salt homeostasis. Last, we
validated ephrin B2 as it was published that it may modulate tubular
structures in medullary kidney epithelial cells through membrane re-
traction and rearrangement of the sites of adhesion to the underlying
basal lamina [34]. The MS and Western Blot (WB) analysis for nephrin
1, uromodulin, ephrin B2 and IST-1 proteins are reported in Fig. 2 and
Table 2. Consistent with the MS data, nephrin 1 was signiﬁcantly up-
regulated in SS vs. both SR and controls, and slightly up-regulated in
SR vs. controls; uromodulin was up-regulated in SS and SR vs. controls
while IST-1 and ephrin B2 were up-regulated in SR vs. control. As
actin intensities from MS data did not change among the three groups
of samples, we decided to use actin staining to normalize all the urine
samples in the WB analysis (Supplementary Fig. 5).
3.5. Biomarkers validation
Since the validation step is a laborious and time consuming process,
we focused only on the proteins that were potentially more related to
hypertension. We queried the Urinary Proteins Biomarker Database
[35] and found some diseases sharing the same biomarkers as the
ones identiﬁed (Supplementary Fig. 6). Therefore, we assumed that
these diseases might share the same injury sites or pathophysiological
Fig. 2. Left panels: scatter plots of the related intensity values fromMS analysis. Right panels: scatter plots of optical density values normalized on actin values and relativeWestern Blot
images using antibodies against nephrin 1, uromodulin, ephrin B2 and IST1 (20 μg of concentrated urinary proteins from different subjects per lane was used for the analysis).*0.01 b P
value b 0.05; **0.001 b P value b 0.01; ***P b 0.001.
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nephrin 1 was found as a relevant biomarker in advanced hypertension
due to preeclampsia [36] while uromodulin has been reported asmark-
er of microalbuminuria progression in type 1 diabetes [37]. Both condi-
tions are known to be linked to progressive renal failure often
associated with hypertension. Thus, we decided to further validate
these two proteins on a larger cohort of patients (19 controls, 16 SRTable 2
Statistical analysis of the urinary markers for small-scale veriﬁcation. Proteins signiﬁcantly mod
tein, protein names, gene names, Uniprot ID and averaged intensities values for each group an
Protein names Gene names Uniprot P value Average
intensity C
Nephrin 1 NEPH1 Q96J84 4.97E-04 69,860.6
Ephrin type-B receptor 2 EPHB2 P29323 2.59E-04 3038.15
Uromodulin UMOD E9PEA4 1.71E-06 2.03E + 08
Increased sodium tolerance 1 IST1 A8KAH5 8.83E-04 142,782and 15 SS) (Supplementary Fig. 7). As reported in Fig. 3, nephrin 1
was signiﬁcantly over-represented in SS patients vs. controls with an
AUC of 0.77, while the AUC for SR patients was clearly lower. Converse-
ly, uromodulin resulted signiﬁcantly over-represented in all hyperten-
sive patients compared to controls and no statistical difference
between SS and SR patients was observed. The AUCs for the prediction
of SS and SR hypertension were 0.80 and 0.79 respectively.ulated either by ANOVA test (P value b 0.01) or T test analysis are reported. For each pro-
alyzed are reported in the table.
Average intensity SR Average
intensity SS
P value
T test C-SR
P value
T test C-SS
P value
T test SR-SS
101,682 126,063 5.04E-03 8.58E-04 4.54E-02
31,176.4 13,283 3.15E-04 ns 3.31E-02
6.54E + 08 7.45E + 08 2.00E-07 2.71E-04 ns
326,882 138,294 1.61E-03 ns 5.89E-03
Fig. 3.Nephrin 1 and uromodulin levels are predictive of salt sensitivity and hypertension. Left panels: scatter plots of optical density values fromWBanalysis using urines from19 controls,
16 SR and 15 SS hypertensive patients. Right panels: ROC curveswere depictedwith associatedAUC and sensitivity and speciﬁcity at the best cut-off point. As optimal cut off pointwe used
the one closest to top-left corner. In the scatter plots, y-axis indicates theODof the target proteinsnormalized against actin values; the lines indicate the optimal cutoff value reported in the
ROC curves. *0.01 b P value b 0.05; **0.001 b P value b 0.01; ***P b 0.001.
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patients
As nephrinuria might be associated to a putative crumbling of the
glomerularﬁltration barrier, we explored the urinary albumin excretionFig. 4. Albumin excretion was analyzed from urine of 56 patients, 19 SS and 37 SR. Upper pa
(mmol/L) concentration for SR and SS patients (albumin:creatinine ratiowere all b3 mg/mmol)
on volume for SR and SS patients (albumin is expressed as mg/L and nephrin as optical densitin 56 hypertensive subjects including also the patients previously ana-
lyzed. As expected, no subject presented microalbuminuria (albumin:
creatinine ratio b 3 mg/mmol) while albumin excretion normalized to
creatinine values was higher in SS than in SR patients (Fig. 4). Interest-
ingly, albumin and nephrin 1 positively correlated exclusively in SSnel represents scatter plot of albumin excretion values (mg/L) normalized on creatinine
. Lower panels show Pearson correlation of albumin and nephrin 1 values both normalized
y (OD)/μL).
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early glomerular damage that might alter the glomerular ﬁltration
barrier.3.7. Uromodulin secretion in hypertension correlates with homozygous
UMOD risk variant and with decreased level of salt excretion
As previously discussed, we found uromodulin signiﬁcantly more
abundant in the urine of both salt sensitive and salt resistant hyperten-
sive patients with respect to normotensive individuals, suggesting that
this alteration is independent from the salt sensitivity. In fact, no signif-
icant differences in UMOD amounts have been observed between salt-
sensitive and salt-resistant urine samples. GWAS studies identiﬁed
common variants in the promoter of the UMOD gene associated to hy-
pertension [38], and, in particular, the UMOD risk variant rs4293393
TTwas recently found associated with higher expression of uromodulin
both at transcript and protein level [33]. Therefore, we analyzed the
frequency of this last variant in the patients enrolled in the study.
We divided the patients in two groups according to urinary
uromodulin levels, using as cutoff the value derived by the ROC curve.
Interestingly, we found that patients secreting higher level of
uromodulin were carriers, with a high frequency (0.75), of the UMOD
risk variant rs4293393 TT suggesting that higher uromodulin excretion
might be linked to amajor protein expression. This ﬁndingmight be ex-
tremely relevant for this disease given the high frequency of UMOD risk
variant in the general population [33]; obviously, further prospective
studies using larger cohort of patients will be necessary to conﬁrm
this data in hypertensive population.
Finally, we evaluated the clinical signiﬁcance of our ﬁndings by test-
ing whether the level of BP and sodium excretion associated toFig. 5. Association of uromodulin excretion level with blood pressure, salt excretion and UMOD
urines from 19 controls and 31 hypertensive patients, the cutoff threshold derived from the ROC
(B, C) scatter plots of values for systolic (SBP) and diastolic (DBP) blood pressure and changes in
levels based on the cutoff ﬁlter. (D) Frequency of the protective (C) and risk (T) alleles of rs42uromodulin level in the urine. Patients with higher level of uromodulin
in the urine displayed lower sodium excretion, indicating an increased
sodium reabsorption along the nephron (Fig. 5).
These data reﬂect for the ﬁrst time a direct link of uromodulin uri-
nary concentration with an altered salt homeostasis in hypertensive
patients.4. Discussion
This study uses a label free quantitative proteomic approach to
address salt sensitivity and hypertension in humans. We used a robust
approach with high sensitivity and reproducibility that allowed the
identiﬁcation of 812 urinary proteins. Among them, we found several
excreted proteins differentially present in both salt sensitive and salt re-
sistant hypertensive patients compared to controls and other proteins
excreted differently in SS compared to SR patients. This ﬁnding supports
the view that high BP and the abnormal response to salt are multi-
factorial and polygenic disorders that are under the control of multiple
mechanisms and complex signaling activities. Using bioinformatics
tools we found pathways potentially involved in salt dependent hyper-
tension. In particular, in SS patients we found down-regulated the pro-
teins glutamyl aminopeptidase A (ENPEP) and alanyl (membrane)
aminopeptidase (ANPEP), which are both enzymes involved in angio-
tensin conversion and belong to the renin–angiotensin system. Interest-
ingly, also in the SS animal model, the renin–angiotensin system in the
kidney has been suggested to play signiﬁcant roles and, consistent with
our data, the SS rat is considered a low-renin model of hypertension
[39,40]. Moreover, in SR patients we found over-represented proteins
related to endocytosis, lysosome and glycolysis; the involvement of
this last pathway is completely new in the hypertension scenario.promoter risk variant: (A) scatter plots of optical density values fromWB analysis using
curve is plotted on the graph (optimal cut off point was the one closest to top-left corner).
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86 V. Matafora et al. / BBA Clinical 2 (2014) 79–87Further, by querying theUrinary Proteins Biomarker Databasewe found
that some of the proteins differently excreted in this study were also
identiﬁed as urinary markers of diabetic nephropathy, ureteropelvic
junction obstruction and IgA nephropathy therefore we speculated
that theymight indicate the same injury sites or pathophysiological pro-
cesses.Moreover,we found nephrin 1 present in an advanced hyperten-
sion disease as preeclampsia and uromodulin asmarker associatedwith
progressive renal failure, as a risk factor for kidney disease, and as a
biomarker for the development of chronic kidney disease.We have con-
ﬁrmed four interesting candidates (nephrin 1, uromodulin, IST1 and
ephrin b2) as potential markers that might justify previously described
key pathophysiological aspects of these diseases. In particular, we
proceeded with the validation of nephrin 1 and uromodulin on a larger
cohort of patients. Nephrin 1 was validated as a biomarker of salt sensi-
tivity. Nephrin 1 is an essential component of the glomerular podocyte
junction and participates in the formation of the glomerular ﬁltration
barrier via interactions with associated proteins. Among others, the
Src family protein kinase Fyn favors nephrin 1 phosphorylation
and the recruitment of adaptor proteins involved in the regulation
of podocyte junction formation and actin cytoskeletal dynamics.
Mutations of podocyte proteins, such as podocin, adducin, laminin-β-2
and knocking out of Fyn or nephrin 1 in mice, induce actin cytoskeleton
rearrangement and disruption of the ﬁltration barrier leading to renal
disease. This evidence supports the hypothesis that in hypertension,
and in particular in salt sensitive subjects, the podocyte integrity
might be compromised [41–44]. As mentioned above, nephrinuria
was also found altered in preeclampsia, a pregnancy-speciﬁc, multi-
systemic disorder characterized by the new-onset of hypertension
[45].
Here, we found that SS patients, besides an increased nephrinuria
compared to SR, show a higher (although within normal values) albu-
min excretion, which positively correlates with nephrin 1 excretion.
This ﬁnding is in line with the view indicating nephrin 1 as a predic-
tive biomarker of glomerular damage earlier thanmicroalbuminuria.
Such hypothesis is also in agreement with a recent study where
nephrinuria was detected in normoalbuminuric compared to
microalbuminuric patients with diabetic nephropathy [46]. Alto-
gether, these ﬁndings streamline the possibility of using nephrin 1
to predict glomerular complications. Obviously, to deﬁnitively
associate nephrinuria with disease progression, other prospective
studies will be necessary.
On the other hand, uromodulin was validated as a marker of hyper-
tension. The exclusive expression of uromodulin in the thick portion of
the ascending limb, where physiologically crucial mechanisms of sodi-
um handling are located, and its potential to act as modulator of other
salt transport systems located downstream, suggests that alterations
of this protein might affect hypertension and renal sodium handling
through an effect on sodium homeostasis. In agreement with our ﬁnd-
ing, Torffvit et al. [47] showed that urinary excretion of uromodulin is
dependent on sodium intake; while Genome Wide Association Study
of BP extremes identiﬁed variants near UMOD associated with hyper-
tension [38] and increased urinary uromodulin levels [48]. Here we
found that uromodulin is more secreted in hypertensive patients with
respect to healthy individuals, and that the level of this protein corre-
lateswith lower sodiumexcretion. These ﬁndings point out the hypoth-
esis that uromodulin increases salt reabsorption favoring high blood
pressure by impairing sodium excretion. Indeed our group has already
demonstrated that, in an animal model of kidney related hypertension,
theNa–K–2Cl (NKCC2) and theNa–Cl (NCC) transporters, two potential
targets of uromodulin action, are up-regulated in the development and
maintenance of the hypertensive disease [49,50].
We also showed that patients secreting increased level of
uromodulin carry the UMOD risk variant PDILT_UMOD_rs4293393
with high frequency. Interestingly, this variant was recently found asso-
ciated to increased level of uromodulin both at transcript and at protein
level [33]. In the same study, the relationship of uromodulin andhypertension was proved in animal models where uromodulin overex-
pression leads to hypertension and renal damage.
Even though we know that hypertension is a complex disease, im-
plying the existence of other factors that inﬂuence blood pressure, our
work highlights key markers of hypertension and salt sensitivity. Both
nephrin and uromodulin are associated to renal damage, therefore
these ﬁndings are open to novel therapeutic targets aimed to preserve
renal function and to lower blood pressure, thus personalizing the phar-
macological treatment of patients.
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